Scarica l'app Stockscreener
0.8025
2.73%
-0.0225
Dopo l'orario di chiusura:
.81
0.0075
+0.93%
Panoramica
Notizia
Cronologia dei prezzi
Financials
Perché ITRM Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$0.825
Aprire:
$0.83
Volume 24 ore:
871.46K
Relative Volume:
1.41
Capitalizzazione di mercato:
$32.10M
Reddito:
-
Utile/perdita netta:
$-35.58M
Rapporto P/E:
-0.3028
EPS:
-2.65
Flusso di cassa netto:
$-42.82M
1 W Prestazione:
-12.45%
1M Prestazione:
-22.09%
6M Prestazione:
-47.20%
1 anno Prestazione:
-35.80%
Intervallo 1D:
$0.8005
$0.8399
Intervallo di 1 settimana:
$0.8005
$0.92
Portata 52W:
$0.8005
$3.02
Iterum Therapeutics Plc Stock (ITRM) Company Profile
Nome
Iterum Therapeutics Plc
Settore
Industria
Telefono
(872) 225-6077
Indirizzo
3 DUBLIN LANDINGS, DUBLIN 1
Confronta ITRM con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ITRM
Iterum Therapeutics Plc
|
0.8025 | 33.00M | 0 | -35.58M | -42.82M | -2.65 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Iterum Therapeutics Plc Stock (ITRM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-05-28 | Aggiornamento | Gabelli & Co | Sell → Hold |
| 2021-03-15 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2020-06-02 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-01-21 | Downgrade | Gabelli & Co | Buy → Sell |
| 2019-12-11 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2019-06-21 | Iniziato | H.C. Wainwright | Buy |
Mostra tutto
Iterum Therapeutics Plc Borsa (ITRM) Ultime notizie
Iterum Therapeutics plc Stock Analysis and ForecastFree Stock Market Trend Analysis - PrintWeekIndia
Is Iterum Therapeutics plc a good long term investmentSuperior risk-adjusted returns - Autocar Professional
What drives Iterum Therapeutics plc stock priceConsistently exceptional gains - Autocar Professional
Iterum Therapeutics Plc (ITRM) Stock: A Year of Market Movement, Down and Up - investchronicle.com
What analysts say about Iterum Therapeutics plc stockHigh-profit capital plays - jammulinksnews.com
Why Iterum Therapeutics plc stock attracts strong analyst attentionMassive Profit Potential - Newser
What makes Iterum Therapeutics plc stock price move sharplyWatchlist Winner Update - Newser
How Iterum Therapeutics plc stock performs during market volatilityFree Access to Investment Community - Newser
OneDigital Investment Advisors LLC Invests $124,000 in Iterum Therapeutics PLC (NASDAQ:ITRM) - Defense World
Iterum Therapeutics (NASDAQ:ITRM) Trading Down 4.2% – Here’s What Happened - Defense World
Iterum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - 富途牛牛
Iterum Strengthens Launch Strategy: 30-Year Pharma Veteran Christine Coyne to Lead ORLYNVAH Commercialization - Stock Titan
Iterum Names Christine Coyne as Chief Commercial Officer to Lead ORLYNVAH™ Launch and Commercial Growth - Yahoo Finance
Certain Options of Iterum Therapeutics plc are subject to a Lock-Up Agreement Ending on 30-JUN-2025. - MarketScreener
Certain Ordinary Shares of Iterum Therapeutics plc are subject to a Lock-Up Agreement Ending on 30-JUN-2025. - MarketScreener
Iterum Therapeutics (ITRM) Releases Positive Phase 3 Trial Resul - GuruFocus
Iterum Therapeutics (ITRM) Releases Positive Phase 3 Trial Results | ITRM Stock News - GuruFocus
New Antibiotic Shows Promise Against Drug-Resistant UTIs: NEJM Evidence Reveals 9.2% Multi-Resistance Rate - Stock Titan
Transcript : Iterum Therapeutics plcSpecial Call - MarketScreener
Research Analysts Set Expectations for ITRM FY2026 Earnings - Defense World
Two Sigma Investments LP Invests $45,000 in Iterum Therapeutics plc (NASDAQ:ITRM) - Defense World
EVERSANA expands commercialisation portfolio with OS Therapies and Iterum Therapeutics partnerships - pharmaphorum
Citadel Advisors LLC Acquires Shares of 21,207 Iterum Therapeutics plc (NASDAQ:ITRM) - Defense World
Iterum Therapeutics (ITRM) Partners with EVERSANA for U.S. Launc - GuruFocus
Iterum Therapeutics announces partnership with EVERSANA - PharmaLive
Iterum Therapeutics inks deal for ORLYNVAH commercialization By Investing.com - Investing.com Nigeria
Iterum Therapeutics inks deal for ORLYNVAH commercialization - Investing.com
Iterum Therapeutics Announces Partnership for Commercialization Services - Yahoo Finance
Breakthrough UTI Drug ORLYNVAH Set for Q4 2025 Launch: First Oral Penem Antibiotic in US History - Stock Titan
Pfizer grants Iterum payment extension for FDA-approved antibiotic By Investing.com - Investing.com South Africa
Pfizer grants Iterum payment extension for FDA-approved antibiotic - Investing.com Australia
Iterum Therapeutics Announces Extension of Term of Promissory No - GuruFocus
Iterum Therapeutics Plc Azioni (ITRM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.97%
0.22%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):